In contrast, Hata et al. reported that BIM protein levels are regulated by MEK/ERK signaling while the expression of PUMA is regulated by PI3K signaling in cancers driven by oncogenic driver mutations on tyrosine kinase, thus resulting in the constitutive activation of downstream kinase signaling pathways including the MEK/ERK and PI3K signaling pathways [44]. This evidence concerns the gene BCL2L11 and cancer.